Aspirin trial signs up 10,000th patient

A landmark has been reached in Australia’s largest-ever clinical trial in general practice, with the 10,000th patient signing up.

It represents a little over the halfway point for the ASPREE study - a vast, multi-million dollar undertaking that has already taken more than a decade of planning.

ASPREE (Aspirin in reducing events in the elderly) is simple in its concept: over-70s are randomised to take either daily low-dose aspirin (100mg) or placebo, and followed up for an average of five years.